Medscape4 天
New Insights into Hepatitis B and Hepatitis Delta Virus Entry
a satellite virusoid employing HBV envelope proteins for the entry into hepatocytes. To date, no effective therapy for HDV infection exists. Thus, entry inhibition may represent the first ...
Medscape21 天
Hepatitis B Core Antigen Expression Pattern Reflects the Response to Anti-Viral Treatment
Background: In hepatitis B early antigen (HBeAg)-negative patients, response predictors to current treatment regimens are not well known. Hepatocyte cell cycle may influence hepatitis B virus (HBV ...
Taiwan News6 天
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy ...
2 SCG101 is designed to target a specific HBV peptide presented on infected cells, as well as hepatocytes with HBV DNA integration. By triggering both cytolytic and non-cytolytic mechanisms, SCG101 ...
GlobalData on MSN6 天
SCG’s HBV T-cell therapy shows promise in Phase I trial
SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...
Morningstar6 天
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy ...
2 SCG101 is designed to target a specific HBV peptide presented on infected cells, as well as hepatocytes with HBV DNA integration. By triggering both cytolytic and non-cytolytic mechanisms ...